1 BTC
=
- USD
iTeos Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About iTeos Therapeutics, Inc. Common Stock
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Market Statistics
Trading Metrics
How to Buy ITOS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ITOS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesLaw firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies, including iTeos Therapeutics, City Office REIT, and Synovus Financial Corp, focusing on recent merger and acquisition transactions.
Law firm Monteverde & Associates is investigating the proposed acquisition of iTeos Therapeutics by Concentra Biosciences, offering $10.047 per share plus contingent value rights.
iTeos Therapeutics has agreed to be acquired by Concentra Biosciences for $10.047 in cash per share, plus a contingent value right. The transaction is expected to close in Q3 2025, subject to customary closing conditions and stockholder approval.
iTeos Therapeutics reported financial results for Q1 2025 and provided updates on its clinical programs, including upcoming data readouts for its TIGIT and adenosine inhibitor candidates.